这笔收购，引发了两大讨论： 其一，康缘药业目前主要的商业化产品及收入来源均为中药产品，“跨界”做GLP-1，在研发进展和成效上争得国内靠前位置，几率有多大？ 其二，中新医药尚未有商业化产品销售，仍处于持续亏损状态，且未来仍需投入大量资金用于 ...

跨界并购，做得好是激发活力，做不好可能是“灭顶之灾”。 撰文| Kathy “双字科”上市公司正接力成为妖股。 妖股第一棒，是已经走出23天21板的多肽概念股双成药业，宣布跨界并购半导体资产后，凭借这笔交易走出了23天21板，难免羡煞旁人。

PHILADELPHIA — The use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with a significant decrease in the risk for early-onset colorectal cancer (EO-CRC) in patients with ...

The company benefits from GLP-1 drug sales and is positioned for high margins and recurring revenues in the growing healthcare market. HIMS achieved positive operating income with 50% revenue ...

It found that over 12 months, 1.4% of adolescents on GLP-1 drugs had a suicide attempt or ideation, compared with 2.3% who weren’t on the medicines. There was no sign of an increase associated ...

The new menu includes five smoothies “created to assist the millions of Americans currently taking prescription GLP-1 medications" Sabrina Weiss is the Editorial Assistant of PEOPLE's food ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered. Advertisement Under the Medicaid system ...

As with any new drug, parents and doctors may worry that the use of GLP-1 weight-loss meds by children and teens might raise psychiatric risks, including the risk for suicide and suicidal thoughts.

Most Patients Can Keep Using GLP-1 Weight Loss Meds Before Surgeries By Ernie Mundell HealthDay Reporter THURSDAY, Oct. 31, 2024 (HealthDay News) -- A new guidance issued jointly by groups ...

The ever-rising popularity of GLP-1 medications is reshaping the landscape of bariatric surgeries — but experts say patients could be overlooking key factors when choosing between the two weight ...

Some 12% — or about 1 in 8 — people living in the U.S. have tried a GLP-1 drug, according to a survey by the Kaiser Family Foundation. And with that drug comes many dietary changes that need ...